Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that its collaboration …
In a research report published Wednesday, MLV analyst Arlinda Lee reiterated a Buy rating on Agios Pharmaceuticals (NASDAQ:AGIO) with a price target of …
Cowen analyst Eric Schmidt maintained an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO), as the company announced new data from its ongoing phase 1 trial …
In a research report issued today, MLV analyst Arlinda Lee initiated coverage on Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and a $123 price …
Canaccord analyst John Newman maintained a Buy rating on Agios Pharmaceuticals (NASDAQ:AGIO) with a price target of $111, as the company will present …
